Lexicon Pharmaceuticals


Cowen Sees Lexicon Pharmaceuticals, Inc. (LXRX) Phase III Results as Promising

Cowen analyst Chris Shibutani remains sidelined, but optimistic on Lexicon Pharmaceuticals (NASDAQ:LXRX) after the firm released a positive top-line readout from InTandem2, the second of its three pivotal Phase III trials …

Wedbush Reiterates Outperform On Lexicon Following Funding Support From JDRF

In a research report released yesterday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Lexicon Pharmaceuticals (LXRX) with a $4 price target, …

Wedbush Reiterates Outperform On Lexicon Following Appointment Of New CEO

In a research report published yesterday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Lexicon Pharmaceuticals (LXRX) with a $4 price target …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts